Journal ArticleDOI
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben Horin,Matti Waterman,Uri Kopylov,Miri Yavzori,Orit Picard,Ella Fudim,Halim Awadie,Batia Weiss,Yehuda Chowers +8 more
Reads0
Chats0
TLDR
The addition of immunomodulators to therapy might be helpful to patients who have lost response to anti-TNF agents owing to formation of antidrug antibodies.About:
This article is published in Clinical Gastroenterology and Hepatology.The article was published on 2013-04-01. It has received 291 citations till now. The article focuses on the topics: Infliximab & Ulcerative colitis.read more
Citations
More filters
Journal ArticleDOI
Crohn's disease
TL;DR: An physician-oriented overview of Crohn's disease in adults is provided, ranging from epidemiology and cause to clinical diagnosis, natural history, patient stratification and clinical management, and ending with an overview of emerging therapies and future directions for research.
Journal ArticleDOI
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher A. Lamb,Christopher A. Lamb,Nicholas A. Kennedy,Tim Raine,P Hendy,P Hendy,Philip J Smith,Jimmy K. Limdi,Jimmy K. Limdi,Bu'Hussain Hayee,Bu'Hussain Hayee,Miranda Lomer,Miranda Lomer,Gareth Parkes,Gareth Parkes,Christian P. Selinger,Christian P. Selinger,Kevin Barrett,R Justin Davies,Cathy Bennett,Stuart Gittens,Malcolm G. Dunlop,Malcolm G. Dunlop,Omar Faiz,Aileen Fraser,Vikki Garrick,Paul D Johnston,Miles Parkes,Jeremy D. Sanderson,Jeremy D. Sanderson,Helen Terry,Daniel R. Gaya,Daniel R. Gaya,Tariq Iqbal,Tariq Iqbal,Stuart A. Taylor,Stuart A. Taylor,Melissa A. Smith,Melissa A. Smith,Matthew J Brookes,Richard Hansen,A Barney Hawthorne +41 more
TL;DR: Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care.
Journal ArticleDOI
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
Frank M. Ruemmele,Frank M. Ruemmele,Frank M. Ruemmele,Gábor Veres,Kaija-Leena Kolho,Anne Griffiths,Arie Levine,Johanna C. Escher,J. Amil Dias,Arrigo Barabino,Christian Braegger,Jiri Bronsky,Stephan Buderus,Javier Martín-de-Carpi,L. de Ridder,Ulrika L. Fagerberg,Jean-Pierre Hugot,Jaroslaw Kierkus,Sanja Kolaček,Sibylle Koletzko,Paolo Lionetti,Erasmo Miele,V.M. Navas Lopez,Anders Paerregaard,Richard K Russell,Daniela Elena Serban,Ron Shaoul,P. van Rheenen,Gigi Veereman,B Weiss,David Wilson,Axel Dignass,A Eliakim,Harland S. Winter,Dan Turner +34 more
TL;DR: These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.
Journal ArticleDOI
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.
TL;DR: An overview of the definition, epidemiology and risk factors for PNR and LOR, as well as the therapeutic options for managing LOR are provided.
Journal ArticleDOI
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar,Yehuda Chowers,Miri Yavzori,Orit Picard,Ella Fudim,Ofir Har-Noy,Uri Kopylov,Rami Eliakim,Shomron Ben-Horin +8 more
TL;DR: Serial measurements showed that ATI development often preceded the onset of clinical flare, and survival free of clinical loss of response was enjoyed by 51% of patients, and serial measurements showed this incidence is reduced by concomitant immunomodulator even in scheduled-therapy patients.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean-Frederic Colombel,William J. Sandborn,Walter Reinisch,Gerassimos J. Mantzaris,Asher Kornbluth,Daniel Rachmilewitz,Simon Lichtiger,Robert H. Diamond,Delma L. Broussard,Kezhen L. Tang,C. Janneke van der Woude,Paul Rutgeerts +11 more
TL;DR: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Journal ArticleDOI
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Filip Baert,Maja Noman,Severine Vermeire,Gert Van Assche,Geert D' Haens,An Carbonez,Paul Rutgeerts +6 more
TL;DR: The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment, and concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Journal ArticleDOI
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Jean-Frederic Colombel,Remo Panaccione,Geert R. D'Haens,Ju Li,Marie R. Rosenfeld,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab as discussed by the authors.
Journal ArticleDOI
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.
Imke Tiede,Gerhard Fritz,Susanne Strand,Daniela Poppe,Radovan Dvorsky,Dennis Strand,Hans A. Lehr,Stefan Wirtz,Christoph Becker,Raja Atreya,Jonas Mudter,Kai Hildner,Brigitte Bartsch,Martin H. Holtmann,Richard S. Blumberg,Henning Walczak,Heiko Iven,Peter R. Galle,Mohammad Reza Ahmadian,Markus F. Neurath +19 more
TL;DR: It is suggested that 6-Thio-GTP derivates may be useful as potent immunosuppressive agents in autoimmune diseases and organ transplantation and in the control of T cell apoptosis by modulation of Rac1 activation upon CD28 costimulation.